Inclusion criteria:

1. Patients who presented with chronic coronary syndrome, underwent PCI and have been on maintenance treatment with DAPT, composed of low-dose aspirin (81mg od) and prasugrel (10 mg od) or ticagrelor (90 mg bid) for at least 30 days. Or patients that presented with an Acute coronary syndrome (ACS) event and underwent PCI and have been on maintenance treatment with DAPT, composed of low-dose aspirin (81mg od) and prasugrel (10mg od) or ticagrelor (90mg bid) for 3 months or greater.
2. Age 18 – 100 years old
3. Provide written informed consent

Exclusion criteria:

1. Prior history of stent thrombosis
2. Acute Coronary Syndrome (ACS) within 3 months.
3. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
4. Renal failure requiring dialysis
5. Patients with known bleeding diathesis or coagulation disorders
6. Known severe hepatic impairment
7. Hemodynamic instability
8. Hypersensitivity to clopidogrel
9. Pregnant and breastfeeding women [women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study]